Open Orphan Plc Earnings Call: Diversifying Amid Strain

Open Orphan Plc ((GB:HVO)) has held its Q4 earnings call. Read on for the main highlights of the call.

Open Orphan Plc’s latest earnings call struck a cautious but constructive tone as management balanced solid strategic progress with sharp financial headwinds. The group proved it can still generate profit in a tough year, yet cash depletion, a smaller order book and pressure on its core human challenge trials leave investors weighing execution risk against a growing, more diversified pipeline.

Resilient Profitability Amid Revenue Pressure

Open Orphan reported full‑year revenue of £46.8m and an operating profit of £1.4m, despite a difficult backdrop and £1.4m of net acquisition losses. The performance confirms an underlying profitable core, but also underscores how sensitive earnings remain to cancellations and lower‑margin work as the business model evolves.

Rebranding Around an Integrated hVIVO Platform

The company completed its integration and rebrand under the single hVIVO banner, consolidating operations into four service lines: consulting, clinical trials, human challenge trials and laboratories. This end‑to‑end platform is designed to reduce reliance on challenge studies alone and position hVIVO as a broader specialist CRO for infectious disease and respiratory drug development.

Building Phase I–III Clinical Trial Reach

Management highlighted a successful push into Phase I work, giving the group capabilities from Phase I through Phase III and across preclinical interfaces. This broader clinical footprint enables cross‑selling, such as running Phase I plus human challenge trial combinations, and opens access to a wider pool of biotech and pharma clients pursuing full development programs.

New Human Challenge Models Enhance Differentiation

Open Orphan reinforced its niche leadership by launching updated influenza challenge models and the world’s only commercial human metapneumovirus (hMPV) model. These additions deepen the company’s differentiated human challenge portfolio, which remains strategically important even as its share of revenue is expected to decline.

Key Contracts Underpin Medium‑Term Pipeline

Commercial momentum included an influenza prophylactic antiviral challenge study with Traws Pharma, with most revenue expected to land in 2026. Management is also close to finalizing a multiyear ILiAD Phase III whooping cough challenge trial, which would provide substantial revenue flow from 2027 and underpin the medium‑term growth story.

Acquisitions Delivered but Mixed Performance

The group completed and integrated two notable deals: Cryostore and German clinical research units, while realigning systems and management. Cryostore contributed £0.8m of high‑margin revenue with strong 90–95% client retention, but the German units delivered £12.3m, falling short of due‑diligence expectations amid weaker sector‑wide RFP conversion.

Laboratory Investments to Lift Margins and Scope

Open Orphan invested in upgraded laboratory capabilities, including Europe’s first digital droplet PCR Hamilton system and next‑generation sequencing. Bringing previously outsourced lab work in‑house should accelerate turnaround times, broaden services and improve margins, supporting the company’s ambition to be a full‑service development partner.

Growing Pipeline and Business Development Activity

New proposal activity rose roughly 50% year‑on‑year in Q1 2026, a key leading indicator of future bookings. The company continues to sign Phase I contracts in the £0.6–1.0m range, and its guidance for high single‑digit revenue growth in 2026 suggests management expects the pipeline to begin offsetting recent volatility.

Cash Burn Raises Near‑Term Liquidity Questions

The cash balance fell from £44.2m to £14.3m during the year, a roughly 67.6% decline driven by acquisitions, working capital and weaker challenge trial bookings. While operations generated £10.4m and capital expenditure remained modest at £1.4m, the scale of cash use puts a spotlight on near‑term funding flexibility and the need to convert pipeline into signed contracts.

Order Book Restated and Shortened

The order book shrank to £30m from a previously reported £43.5m, reflecting both real weakness and a stricter recognition method that now only counts contracted clinical trial agreement values. This restatement results in a shorter‑term, more conservative booking profile, which may improve transparency but reduces visibility for investors watching future revenue cover.

Headwinds Hit Human Challenge Trial Revenue

Human challenge trial revenue dropped sharply in 2025 due to an unusually high number of cancellations, far above the historical average. As a result, HCT’s contribution is expected to fall from more than 85% of revenue in 2024 to under 50% in 2025, marking a structural pivot but also exposing near‑term earnings to the growing pains of diversification.

Revenue Volatility from Contract Cancellations

Multiple cancellations in April and May 2025 materially weighed on the top line and highlighted the inherent lumpiness of the project‑based model. This volatility makes forecasting more difficult and underlines the importance of building a broader base of smaller, repeatable contracts across the clinical and lab portfolio.

Margin Pressure from Diversification Strategy

Management acknowledged that human challenge trials carry superior margins compared with standard clinical work, where competition is more intense. As non‑HCT services scale, margins are likely to compress in the near term, with the hope that volume growth, operational leverage and in‑house lab work gradually restore profitability.

Rising Operating Costs and Lease Burden

Operating cash outflows were compounded by higher lease payments, which increased by an estimated £2–3m after a rent‑free period ended at the Canary Wharf facility. Alongside around £10.5m of acquisition consideration and roughly £4.0m of working capital outflow, these costs contributed to the sharp reduction in the year‑end cash position.

Dividend Suspension Signals Capital Preservation

In a move likely to disappoint income‑focused shareholders, the board opted not to pay the FY2025 dividend of £1.4m. Management framed the decision as prudent capital preservation to support ongoing investment and navigate a period of elevated cash demands and uncertain booking trends.

Forward Guidance: Modest Growth, Execution Risk

Looking ahead, management expects HCT to contribute less than half of revenue, with over 50% coming from diversified non‑HCT services and high single‑digit revenue growth in 2026. A stronger proposal pipeline, the Traws Pharma study and a potential ILiAD Phase III contract support this outlook, but lower visibility and tight cash levels mean delivery on these plans will be closely watched.

Overall, Open Orphan’s call portrayed a business at an inflection point, trading near‑term financial strain for a broader, more sustainable platform. Investors will need to balance optimism about a growing pipeline and unique challenge models against concerns over cash, order book compression and thinner margins as the company executes its diversification strategy.